Dr. Leighl, lung cancer expert from Princess Margaret Hospital in Toronto, continued her summary of the leading highlights in lung cancer from 2012 with coverage of new information on XALKORI for patients with either an ALK rearrangement or the newly identified ROS-1 rearrangement.
The video and audio versions of the podcast on this part of her program are below, along with the figures:
[powerpress]
Dr. Leighl Highlights in LC 2012 Pt 2 ALK and ROS Rearr NSCLC Audio Podcast
Dr. Leighl Highlights in LC 2012 Pt 2 ALK and ROS Rearr NSCLC Figs
More of her presentation coming very soon!
